Bcl-2 family plays an important role in cell apoptosis pathway. The ratio of pro-apoptosis members and anti-apoptosis members closely correlates with tumorigenesis, tumor radiosensitivity and progno-sis. Recent years ,according to the correlation of Bcl-2 family and tumor radiosensitivity, many researchers want to find new therapeutic strategies that target Bcl-2 in clinical radiotherapy.

In recent years,the incidence rate and mortality rate of non-small cell lung cancer (NSCLC) in elderly patients have been increasing.The therapy scheme consists of surgery,radiotherapy,chemotherapy and target therapy,with the purpose of prolonging survival time and improving life quality.But there is no unified standards of treatment in elderly non-small cell lung cancer.

Objective To investigate the clinical characteristics and the risk factors of hospital-acquired pneumonia(HAP) in the patients with intracerebral hemorrhage(ICH) .Methods The clinical data of 1 184 cases of ICH complicating HAP from Sep .2009 to Sep .2012 were analyzed retrospectively and statistically .Results The incidence rate of HAP was 13 .0% in these ICH patients , the detected pathogens were in turn Gram-negative bacilli(63 .4% ) ,Gram-positive cocci(26 .7% ) and fungi(9 .9% );the risk factors of HAP in ICH patients were related with the age of patients ,underlying disease ,length of hospital stay ,conscious state ,tracheoto-my ,amount of cerebral hemorrhage ,bulbar palsy and nutritional status .Conclusion The patients with ICH are easy to develop HAP .Aiming at the above risk factors ,the comprehensive measures should be adopted to reduce the incidence rate of HAP in ICH patients .

Pemetrexed is a novel antifolate which is approved in the USA and Europe for the treatment of non-small-cell lung cancer (NSCLC).Researches reveal that pemetrexed enhances radiation-induced cell inactivation.A series of clinical trials of pemetrexed combined with radiotherapy for NSCLC also demonstrated that pemetrexed provides similar efficacy with lower toxicity and better tolerability than other third-generation chemotherapy drugs.

Preoperative radiotherapy combined with chemotherapy and (or) targeted therapy not only reduces the local recurrence of locally advanced rectal cancer and increases the rate of anal preservation and pathologic complete response,but also improves patient compliance.Preoperative neoadjuvant therapy will gradually become the standard treatment for locally advanced rectal cancer.

The single brain metastases of lung cancer is defined as limited brain metastases .Mechanism of brain metastasis from lung cancer remains to be further studied .Based on surgery ,radiotherapy ,and chemother-apy,the comprehensive treatment on limited brain metastasis of non -small cell lung cancer gets a better result , however ,the indications for combination therapy must be strictly controlled .Increasing radiation doses of local tumor area,followed by whole-brain radiotherapy,can improve tumor local control rate and prolong overall sur-vival.Prophylactic irradiation of whole brain showed no evidence on prolonging the overall survival .For patients with poor general state,targeted drugs combined with whole brain radiotherapy can be tolerated well ,as well as prolonged the overall survival to ertain extent .

Endostatin is a novel anti-angiogenic drug which through multiple pathway inhibits vascular endothelial growth factor expression,to achieve the purpose of the inhibition of tumor angiogenesis.The drug in the treatment of non-small cell lung cancer in pre-clinical study and clinical application show that:used alone have anti-tumor effect; combined with radiotherapy and chemotherapy can obtain short-term curative effect,and does not increase treatment related toxicity.The adverse effect of the drug is mild and can be well tolerated.

During radiotherapy, ionizing radiation can damage some structures of the heart, including pericardium, myocardium, cardiac valve, conducting system, and coronary artery. Radiation-induced cardiac injury can manifest as abnormalities in many aspects including myocardium enzymes, perfusion imaging, electrocardiogram, strain rate imaging.

Objective To compare the efficacy and toxicity of inductive chemotherapy with pemetrexed followed by radiotherapy for patients with lung adenocarcinoma .Methods Patients with stage Ⅲa/b or Ⅳ and histologically confirmed lung adenocarcinoma were evaluated from July 2008 to April 2012 ( n=95 ) .Patients re-ceived inductive chemotherapy with pemetrexed or paclitaxel followed by thoracic radiotherapy or chemotherapy with pemetrexed alone,respectively.Primary end point was the tumor response rate (RR),progression-free sur-vival(PFS),1-year survival rate and toxicity.Results Tumor RR were 83.3%,81.8%and 62.5% in three groups of inductive chemotherapy with pemetrexed or paclitaxel followed by thoracic radiotherapy or chemotherapy with pemetrexed alone ,respectively.PFS was 12.0 months,10.9 months and 5.7 months.The 1-year survival rate was 80.0%,78.7%and 46.8%.Tumor RR and PFS were statistically superior in pemetrexed/radiotherapy versus pemetrexed alone ,and toxicity was significantly lower than in paclitaxel /radiotherapy.Conclusion The treatment of pemetrexed/radiotherapy for lung adenocarcinoma could prolong the survival of patients .Compared with the treatment of paclitaxel/radiotherapy ,pemetrexed/radiotherapy provides similar efficacy with better tolera-bility and more convenient administration .

Recently,the incidence rate of small cell lung cancer in elderly patients has been increasing . The mainly therapeutic approach of small cell lung cancer consists of radiotherapy ,chemotherapy and surgery ,with the treatment purpose of prolonging survival time and improving life quality .As the huge development of accurate radiotherapy technology occurred in the past a few years ,radiotherapy could play more and more important roles in the treatment with elderly patients .Yet,there is no unified standards of treatment for small cell lung cancer in eld-erly patients.Therefore,we give a review on the latest processes and research on the treatment of small cells lung cancer in elderly patients .